Tag: Nihss

Following a stroke treated with tissue plasminogen activator (tPA), the risk of recurrent ischemic events is high, but so is the risk of hemorrhagic conversion. The complex decision of when to start anticoagulation after tPA requires careful consideration of this delicate balance between preventing another clot and minimizing bleeding risk.

Cardioembolism, often from atrial fibrillation (AFib), accounts for about 20% of all ischemic strokes. For these patients, a critical question is 'What is the 1 2 3 4 rule for anticoagulation stroke?' This framework guides treatment timing to prevent recurrence while minimizing risk.